Börse:
3,340$
-0,90%
Echtzeit-Aktienkurs Affimed NV
Bid:
3,271$
Ask:
3,408$
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 208,50 Mio. EUR (62,43 Mio. x 3,340$) | |
| Website: | - | |
| Sektor: | Medizin / Biotech | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 13,25 | 15,90 | 68,93 | 7,45 |
| KGV | - | - | - | - |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Affimed NV Aktie
Börsenkurse Affimed NV
| Lang & Schwarz | 2,981€ | 8290 | 3,010€ | 8290 | 2,996€ | -0,63% |
| Tradegate | 2,840€ | 1411 | 3,140€ | 1273 | 2,990€ | -2,29% |
| Dollar Indikation | 3,271$ | 0 | 3,408$ | 0 | 3,340$ | -0,90% |
| Euro Indikation | 2,920€ | 0 | 3,060€ | 0 | 2,990€ | -2,29% |
| Börse Stuttgart | 2,920€ | 0 | 3,060€ | 0 | 2,990€ | 1,70% |
Fundamentaldaten der Affimed NV Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 28,00 Mio. | -22,98 Mio. | -22,98 Mio. | -0,38 | 0,00% | - | 7,45 |
| 2017 | 2,27 Mio. | -34,11 Mio. | -34,09 Mio. | -0,78 | 0,00% | - | 68,93 |
| 2016 | 6,99 Mio. | -35,70 Mio. | -35,64 Mio. | -1,07 | 0,00% | - | 15,90 |
| 2015 | 8,39 Mio. | -22,44 Mio. | -22,44 Mio. | -0,79 | 0,00% | - | 13,25 |
| 2014 | 4,49 Mio. | -0,56 Mio. | -0,34 Mio. | -0,02 | 0,00% | - | 17,86 |
Profil der Affimed NV Aktie
Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. Affimed was founded in 2000 and is headquartered in Heidelberg, Germany.Anlagetrends zur Affimed NV Aktie
Trends
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen